FMP
NASDAQ
0.786 USD
0.0459 (5.84%)
Dr. Javier Szwarcberg M.D., M.P.H.
Healthcare
Biotechnology
https://www.sprucebiosciences.com
NASDAQ
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovar...
0001683553
US85209E1091
85209E109
2001 Junipero Serra Boulevard
415 655 4168
US
29
Oct 9, 2020
0001683553
NASDAQ
Biotechnology
Healthcare
85209E109
US85209E1091
US
0.79
2.69
1.21M
32.34M
-
0.679-5.95
0.78
-
-
-
-
-0.63
-
https://www.sprucebiosciences.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.